Europe PMC
Cure8 research brief
Why This Matters
Identifies oral microbes that may appear in the gut of people with IBD and PSC, which could help researchers understand disease mechanisms and eventually inform diagnostics or microbiome-targeted strategies.
Who Should Pay Attention
Researchers studying the microbiome and IBD, clinicians interested in emerging microbiome science, and patients curious about microbiome research (especially those with UC or PSC).
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This preprint analyzes oral and gut whole metagenome sequencing from 191 participants (IBD subtypes, IBD with PSC, and controls) to look for oral microbes that appear in the gut.
The authors report specific oral species (for example, Gemella sanguinis, Fusobacterium nucleatum, Veillonella rogosae) enriched in saliva/tongue and also found enriched in feces of people with ulcerative colitis and validate findings in external gut metagenomes.
The study suggests an “oral–gut microbial axis” where oral bacteria may translocate and contribute to gut microbial differences in IBD and PSC. The paper also notes smoking history correlated with oral microbiome shifts toward a UC-like profile in controls.
This is a preprint abstract and the summary here is grounded in the source-provided abstract rather than a full peer-reviewed paper. It reports associations and microbial signatures, not clinical interventions or proven causal mechanisms.
Keep In Mind
Preprint-level evidence from metagenomic analyses; results are reproducible across cohorts but remain associative. Does not imply clinical treatments or diagnostic tests are ready for routine care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEurope PMC
AuthorsKe S, Zhou Z, Yin X +9 more
Study typePreprint
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Sutterella Inhibition of Aryl hydrocarbon receptor Interleukin-22 signaling and worsening of intestinal inflammation byspecies.
Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.
A preliminary study of HMGB1 defense in Crohn's disease
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...